|Videos|March 15, 2022
Decentralized Clinical Trials in a Covid-19 Landscape
Author(s)YPrime
YPrime President, Mark Maietta, discusses the future of decentralized clinical trials following Covid-19. Adaptations will need to be made as DCT is here to stay.
• Regulatory has begun to investigate new methods and technologies for the clinical trial process.
• Clinical trials will have more decentralized components going forward.
• The key is matching a protocol and patient with the new components of DCT.
Related Content
Trending on Applied Clinical Trials Online
1
Workflow in the Age of AI
2
The AI Churn Trap in Life Sciences and How to Break It
3
ACT Brief: Inspection Readiness Throughout Lifecycle, AI Churn and Operational Discipline, and Global Trial Stakeholder Alignment
4
ACT Brief: Execution Failures and Upstream Origins, European Data Governance Reshaping CROs, and Phase-Dependent Trial Competition
5